New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts
Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Posts navigation Older postsNewer posts